Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients-Reference-Cited by-同舟云学术

Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients

Published:2019-05-28 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Amini Leila,Vollmer Tino,Wendering Desiree J.,Jurisch Anke,Landwehr-Kenzel Sybille,Otto Natalie Maureen,Jürchott Karsten,Volk Hans-Dieter,Reinke Petra,Schmueck-Henneresse Michael

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference100 articles.

1. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy;Harvala;J Med Virol.,2013

2. The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation;Tong;Transplantation.,2002

3. Use of cidofovir for cytomegalovirus disease refractory to ganciclovir in solid organ recipients;Bonatti;Surg Infect,2017

4. Infections and organ transplantation: new challenges for prevention and treatment–a colloquium;Grossi;Transplantation.,2012

5. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients;Kumar;Am J Transplant.,2009

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effector memory–type regulatory T cells display phenotypic and functional instability;Science Advances;2024-09-06

2. Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy;Frontiers in Molecular Medicine;2024-02-01

3. The Entangled World of Memory T Cells and Implications in Transplantation;Transplantation;2023-12-13

4. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein–Barr virus–associated post-transplant lymphoproliferative disorder;Kidney International;2022-12

5. Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients;Molecular Therapy - Methods & Clinical Development;2022-06